NVS

Q: What is the price of Novartis (NVS) today?

The current price of Novartis (NVS) is $ 155.47, representing a 58.13% gain over the past year. The stock began the year trading around $ 137.87 and is currently priced at $ 155.47. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Novartis (NVS) pay dividends?

In the last year, Novartis (NVS) distributed dividends in the month of March, totaling $ 3.10. The Dividend Yield for the last 12 months is 4.53%.

Q: Is Novartis (NVS) a good investment?

Novartis (NVS) is currently trading at $ 155.47 with a P/E ratio of 21.09%. This represents a 2,951% premium compared to its historical average P/E. Over the past year, the stock has gained 58.13 and paid $ 3.10 in dividends, resulting in a dividend yield of 4.53%. The total shareholder return over the same period was 58.13%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Novartis AG

Price

$ 155.47

return (12m)

58.13%

p/e

21.09

p/bv

6.34

DIVIDEND YIELD

4.53%

NVS price

NVS

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment NVS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-1.90%

3 months

11.99%

1 year

58.13%

2 years

80.78%

5 years

125.94%

10 years

237.02%

Fundamentals NVS

review the fundamentals of Novartis shares

P/E

21.09

Sector: -2.15 Industry: 0.38

P/S (PSR)

5.20

Sector: 1.92 Industry: 2.43

P/BV

6.34

Sector: 2.10 Industry: 2.24

DIVIDEND YIELD (DY)

4.53%

Sector: - Industry: -

ROA

12.60%

Sector: -25.33% Industry: -23.48%

ROE

30.04%

Sector: -29.65% Industry: -31.19%

ROIC

10.73%

Sector: -418.66% Industry: -76.94%

NET MARGIN

24.67%

Sector: -27.82% Industry: -30.15%

GROSS MARGIN

75.83%

Sector: 44.91% Industry: 51.03%

OPERATING MARGIN

31.13%

Sector: -22.85% Industry: -26.89%

EV/EBITDA

12.93

Sector: -0.40 Industry: 1.11

EV/EBIT

16.86

Sector: -1.68 Industry: -0.22

PRICE-TO-ASSETS

2.66

Sector: 1.13 Industry: 1.20

BVPS

24.31

Sector: 3.83 Industry: 5.09

EPS

7.30

Sector: -0.89 Industry: -0.80

EQUITY-TO-ASSETS RATIO

0.42

Sector: 0.44 Industry: 0.46

LIABILITIES / ASSETS

0.58

Sector: 0.46 Industry: 0.50

CAGR REVENUE 5 YEARS

1.40%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-10.26%

Sector: - Industry: -

FAIR VALUE OF Novartis ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 155.47

Fair Value

$ 0.00

Upside/Downside Return potential.

-59.36%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals NVS

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
LLY	40.57	35.11	86.53%	0.67%	$ 837.34 B	31.66%
ISRG	56.19	8.94	15.92%	0.00%	$ 160.48 B	28.38%
TMO	27.56	3.45	12.52%	0.35%	$ 184.79 B	15.05%
SNY	12.82	1.39	10.86%	4.62%	$ 116.90 B	18.68%
ABT	27.37	3.48	12.73%	2.34%	$ 178.54 B	14.72%
MDT	24.09	2.26	9.38%	3.27%	$ 111.15 B	13.00%
CVS	52.79	1.24	2.35%	3.62%	$ 93.33 B	0.44%
GSK	14.82	5.29	35.71%	2.96%	$ 113.04 B	17.48%
BSX	32.15	0.00	0.00%	0.00%	$ 93.16 B	14.44%
TMDX	17.99	7.24	40.22%	0.00%	$ 3.42 B	31.43%
HCA	15.86	-38.82	-244.82%	0.62%	$ 107.58 B	8.97%
IDXX	43.01	28.38	65.99%	0.00%	$ 45.56 B	24.62%
RMD	22.02	5.18	23.51%	1.04%	$ 32.72 B	27.53%
DHR	37.39	2.57	6.88%	0.67%	$ 135.12 B	14.71%
INMD	9.26	1.27	13.73%	0.00%	$ 868.77 M	25.32%
PHG	24.85	2.00	8.06%	3.27%	$ 25.78 B	5.07%
FMS	11.36	0.77	6.75%	3.51%	$ 12.82 B	5.02%
SYK	39.12	5.66	14.48%	1.03%	$ 126.98 B	12.92%
CI	10.45	0.00	0.00%	2.26%	$ 71.83 B	2.50%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

NVS Historical Dividends

current DY: 4.53%

5-year average DY: 0.00%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	03/11/2026	03/16/2026	3,10240000
Dividends	03/12/2025	04/25/2025	3,86950000
Dividends	03/08/2024	04/19/2024	3,77700000
Dividends	03/10/2023	03/20/2023	3,46900000
Dividends	03/09/2022	03/17/2022	3,32530000
Dividends	03/05/2021	03/15/2021	3,37800000
Dividends	03/04/2020	03/12/2020	3,04200000
Dividends	03/05/2019	03/13/2019	2,86500000
Dividends	03/07/2018	04/25/2018	2,97700000
Dividends	03/03/2017	04/20/2017	2,74600000
Dividends	02/26/2016	04/15/2016	2,76200000
Dividends	03/04/2015	04/20/2015	2,81700000
Dividends	03/03/2014	04/10/2014	2,71900000
Dividends	02/28/2013	04/05/2013	2,53000000
Dividends	02/29/2012	04/05/2012	2,46000000
Dividends	02/28/2011	04/08/2011	2,35300000
Dividends	03/04/2010	04/13/2010	1,98700000
Dividends	02/26/2009	04/06/2009	1,72000000
Dividends	02/28/2008	04/11/2008	1,47200000
Dividends	03/08/2007	04/10/2007	1,08100000
Dividends	03/02/2006	04/03/2006	0,89400000
Dividends	03/03/2005	04/06/2005	0,98570000
Dividends	02/26/2004	03/30/2004	0,80600000
Dividends	03/06/2003	04/07/2003	0,70000000
Dividends	03/25/2002	04/22/2002	0,52200000
Dividends	03/26/2001	04/20/2001	0,50200000

ABOUT Novartis

Novartis AG

Average Investor10 user rating

4.0 (104 people)

United States

30 years

Founded: 1996

1996

Time since IPO - 30 years

105.794

Employees

Novartis AG is a Switzerland-based pharmaceutical company operating in the Healthcare sector, with a focus on innovative medicines and biotechnology. Headquartered in Basel, Switzerland, the company serves global markets through research, manufacturing, and commercial operations across multiple regions.

Novartis concentrates primarily on prescription medicines and advanced therapies, including biologics, gene therapies, and targeted treatments for complex diseases. Its portfolio spans key therapeutic areas such as oncology, cardiovascular diseases, immunology, neuroscience, and rare diseases.

The company maintains a global footprint across the Americas, Europe, Asia-Pacific, Africa, and the Middle East. Distribution channels include hospitals, clinics, retail pharmacy networks, and public health systems.

Novartis operates through integrated research and development centers, biotechnology facilities, and pharmaceutical manufacturing units. Market dynamics affecting its performance include patent cycles, regulatory frameworks, R&D investment requirements, pricing pressures, and global healthcare demand.

The company employs tens of thousands of people worldwide and supports its innovation pipeline through sustained investment in research and strategic partnerships.

Novartis shares trade in Switzerland on the SIX Swiss Exchange and in the United States through American Depositary Receipts (ADRs) under the ticker NVS.

History and Development

Novartis was formed in the mid-1990s through the merger of Ciba-Geigy and Sandoz, combining chemical, pharmaceutical, and biotechnology expertise into a single global entity.

Following its creation, the company focused on integrating operations, harmonizing research pipelines, and expanding its global presence. Over time, it strengthened its position in innovative medicines while also developing its generics and biosimilars operations through its Sandoz division.

Throughout the 2000s and 2010s, Novartis expanded its therapeutic portfolio and increased investments in biotechnology and advanced research platforms.

In recent years, the company has emphasized high-value innovative medicines, strategic portfolio optimization, and expansion of advanced therapies, while adapting to evolving regulatory environments and healthcare demands.

Today, Novartis positions itself as a global pharmaceutical company centered on innovation, specialized treatments, and long-term research-driven growth.

Additional Information

Novartis AG (United States) is listed on the NYSE and has a market capitalization of $294.97 Billions, with shareholders equity totaling $46.55 Billions.

The company employs approximately 105.794 people and operates in the Health sector, within the Main Medications industry.

Over the past 12 months, Novartis AG reported $56.67 Billions in revenue, generating net income of $13.98 Billions.

Key financial metrics include a P/E ratio of 21.09, a price-to-book (P/B) ratio of 6.34, and a trailing twelve-month dividend yield of 4.53%.

The company trades under the ticker NVS.

Market cap

$ 294.97 Billions

Net worth

$ 46.55 Billions

$ 46,549,000,000.00

Assets

$ 110.95 Billions

$ 110,949,000,000.00

Total Shares Outstanding

1.92 Billion

1,915,000,000

Average Daily Trading Volume

$ 2.51 Millions

$ 2,508,383.64

Sector

Health

Industry

Main Medications

NVS

revenue by Business Segment Novartis

Revenue by Region Novartis

NVS revenue and profits

Financial Results NVS

DRAG THE FRAME TO SEE MORE DATA

NVS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

LBPSW - 4D pharma

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-300.00%

P/BV

0.00

CVS - CVS Health

$ 79.16 20,24% (12M)

P/E

52.79

3.62%

ROE

2.35%

P/BV

1.24

CI - Cigna

$ 278.37 --13,14% (12M)

P/E

10.45

2.26%

ROE

0.00%

P/BV

0.00

CNC - Centene

$ 37.27 --40,26% (12M)

P/E

-2.59

0.00%

ROE

-33.28%

P/BV

0.86

HUM - Humana

$ 197.45 --30,67% (12M)

P/E

17.96

1.99%

ROE

6.70%

P/BV

1.20

HCA - HCA Healthcare

$ 510.27 53,37% (12M)

P/E

15.86

0.62%

ROE

-244.82%

P/BV

-38.82

LLY - Eli Lilly

$ 959.08 31,90% (12M)

P/E

40.57

0.67%

ROE

86.53%

P/BV

35.11

TMO - Thermo Fisher Scientific

$ 503.56 18,34% (12M)

P/E

27.56

0.35%

ROE

12.52%

P/BV

3.45

LBPSW - 4D pharma

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-300.00%

P/VP

0.00

CVS - CVS Health

$ 79.16 20,24% (12 M)

P/L

52.79

3.62%

ROE

2.35%

P/VP

1.24

CI - Cigna

$ 278.37 --13,14% (12 M)

P/L

10.45

2.26%

ROE

0.00%

P/VP

0.00

CNC - Centene

$ 37.27 --40,26% (12 M)

P/L

-2.59

0.00%

ROE

-33.28%

P/VP

0.86

HUM - Humana

$ 197.45 --30,67% (12 M)

P/L

17.96

1.99%

ROE

6.70%

P/VP

1.20

HCA - HCA Healthcare

$ 510.27 53,37% (12 M)

P/L

15.86

0.62%

ROE

-244.82%

P/VP

-38.82

LLY - Eli Lilly

$ 959.08 31,90% (12 M)

P/L

40.57

0.67%

ROE

86.53%

P/VP

35.11

TMO - Thermo Fisher Scientific

$ 503.56 18,34% (12 M)

P/L

27.56

0.35%

ROE

12.52%

P/VP

3.45

Frequently Asked Questions

What is the price of Novartis (NVS) today?

The current price of Novartis (NVS) is $ 155.47, representing a 58.13% gain over the past year. The stock began the year trading around $ 137.87 and is currently priced at $ 155.47. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Novartis (NVS) pay dividends?

In the last year, Novartis (NVS) distributed dividends in the month of March, totaling $ 3.10. The Dividend Yield for the last 12 months is 4.53%.

Is Novartis (NVS) a good investment?

Novartis (NVS) is currently trading at $ 155.47 with a P/E ratio of 21.09%. This represents a 2,951% premium compared to its historical average P/E. Over the past year, the stock has gained 58.13 and paid $ 3.10 in dividends, resulting in a dividend yield of 4.53%. The total shareholder return over the same period was 58.13%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Novartis (NVS) stock?

You can buy Novartis (NVS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol NVS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Novartis (NVS) yield today?

Over the past month, Novartis (NVS) has returned -1.90% — 58.13% over the past year, and 125.94% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 6.97 per share in dividends, resulting in a dividend yield of 4.53%.

If you were to purchase 100 shares of Novartis (NVS) today at the current price of $ 155.47 your total investment would be $ 15,547.00.

Based on historical performance, the investment would have grown to approximately:

$ 24,584.47 after 1 year
$ 35,126.89 after 5 years
$ 52,396.50 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NVS

Novartis AG

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NVS

review the fundamentals of Novartis shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 4.53%

5-year average DY: 0.00%

type

Ex - Dividend Date

payment date

value

ABOUT Novartis

Novartis AG

United States

30 years

1996

105.794

History and Development

Additional Information

PROFIT X PRICE NVS

Financial Results NVS

NVS cash flow

Asset, Revenue and Profit Growth - NVS

NVS balance sheet

LBPSW - 4D pharma

CVS - CVS Health

CI - Cigna

CNC - Centene

HUM - Humana

HCA - HCA Healthcare

LLY - Eli Lilly

TMO - Thermo Fisher Scientific

LBPSW - 4D pharma

CVS - CVS Health

CI - Cigna

CNC - Centene

HUM - Humana

HCA - HCA Healthcare

LLY - Eli Lilly

TMO - Thermo Fisher Scientific

Frequently Asked Questions